Evidence map›Paper›PMID 16891368›Full record

ArticleBiophysical journal2006

A model structure for the heterodimer apoA-IMilano-apoA-II supports its peculiar susceptibility to proteolysis.

Alessandro Guerini Rocco, Luca Mollica, Elisabetta Gianazza, Laura Calabresi, Guido Franceschini, Cesare R Sirtori, Ivano Eberini

Open access · bronzeAbstract read
In one paragraph

Article in Biophysical journal, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Alessandro Guerini RoccoGruppo di Studio per la Proteomica e la Struttura delle Proteine, Centro E. Grossi Paoletti, Dipartimento di Scienze Farmacologiche, Università degli Studi di Milano, Milan, Italy.
Luca Mollica
Elisabetta Gianazza
Laura Calabresi
Guido Franceschini
Cesare R Sirtori
Ivano Eberini
University of Milan · ITDulbecco Telethon Institute · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this study, we propose a structure for the heterodimer between apolipoprotein A-I(Milano) and apolipoprotein A-II (apoA-I(M)-apoA-II) in a synthetic high-density lipoprotein (HDL) containing L-alpha-palmitoyloleoyl phosphatidylcholine. We applied bioinformatics/computational tools and procedures, such as molecular docking, molecular and essential dynamics, starting from published crystal structures for apolipoprotein A-I and apolipoprotein A-II. Structural and energetic analyses onto the simulated system showed that the molecular dynamics produced a stabilized synthetic HDL. The essential dynamic analysis showed a deviation from the starting belt structure. Our structural results were validated by limited proteolysis experiments on HDL from apoA-I(M) carriers in comparison with control HDL. The high sensitivity of apoA-I(M)-apoA-II to proteases was in agreement with the high root mean-square fluctuation values and the reduction in secondary structure content from molecular dynamics data. Circular dichroism on synthetic HDL containing apoA-I(M)-apoA-II was consistent with the alpha-helix content computed on the proposed model.

Indexed as

Computer SimulationModels, MolecularApolipoprotein A-IApolipoprotein A-IIDimerizationHumansHydrolysisLipoproteins, HDLMutationPhosphatidylcholinesProtein Structure, Secondary1-palmitoyl-2-oleoylphosphatidylcholineApolipoprotein A-IApolipoprotein A-IIapolipoprotein A-I MilanoLipoproteins, HDLPhosphatidylcholines

Identifiers

PMID16891368
PMCPMC1578475
OpenAlexW2058209362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.